Date: 29th March 2023
Location: Digital meeting – Zoom link


1. Welcome

Torbjörn Lundgren welcomed online participants and was elected chairperson for the meeting. Bengt von Zur-Mühlen was elected secretary.

2. Introduction of participants

3. Approval of agenda

No additions.

4. Minutes from last meeting 25th October 2022.

The minutes were approved.

5. Guidelines of the Nordic Pancreas and Islet Transplant Group (NπTG) in Scandiatransplant

The group was founded in 2013. Torbjörn Lundgren read through the guidelines and clarified some ambiguities. It was decided that Torbjörn Lundgren and Hanne Scholz propose that our guidelines to be revised so that cell therapies and ATMP (Advanced Therapy Medicinal Products) for the treatment of diabetes can be included. The board of Scandiatransplant has its next meeting on 18th May. NπTG meetings should be announced at least 4 weeks ahead and an agenda should be available at least 2 weeks ahead of the planned meeting. Chairman is elected every third year with a possibility for extension to 3+3 years. Next time for election is in 2024 (Face to Face meeting in the fall).
6. Local reports

Stockholm – one islet last year, 6 pancreas tx since October

Uppsala – no islets last year, one islet 6 weeks ago. One pancreas lost in thrombosis. 2 on the islet-waiting list

Gothenburg – 2 SPK uneventful, 5-6 patients on the islet waiting list.

Oslo - 3 SPK 2 PA, one reop for bleeding, one allo islets, two auto islets since October

Tartu – 5 SPK since October, no severe complications. No portal vein elongation.

Copenhagen – No pancreas since October (3 earlier in 2022)

No big changes in how the protocols are applied locally.

One case was discussed: A girl 16 years old, refugee from Africa, ready for kidney-Tx in Stockholm. Is it too early for SPK? The kidney alone can also improve the diabetes care and there should be more criteria besides the T1D diagnosis. The group suggested that it may be early for pancreas, but it has to be dealt with/decided at the center getting the referral.

7. News from the islet lab

Hanne Scholz reported shortly about the Vertex (VX880 pluripotent-derived insulin producing stem cell) study and the approvals from regulatory authorities in the Nordics. In the US two patients have received half dose (safety-part A). 1/5 Patient has received full dose (part B). In part C Europe will be included. Approvals should be ready before the summer 2023 for most of the centers (7 centers).

Trials in pipeline hypimmune islets with no need of immunosuppression. The results from this study can be a game changer in the field of diabetes treatment.

The isolations are working very well and the importance of using calcium has improved the success rate. Few pancreas offers in the last year. Many offered pancreases are older than the upper limit of 65 years.

8. Helmsley charitable trust

Project with pancreases from diseased donors with type 1 diabetes. Within Scandiatransplant there has yearly been 5-6 T1D DD. It is important to identify more possible pancreases so they can be isolated within the study.
9. Ongoing and planned studies

- CIT study – 7 patients on the waiting lists.
- QoL study with Anette Lennerling
- Bengt Gustafsson is looking if it is possible to report Nordic pancreas results. It would be good if a younger researcher could be included in this work.

10. Registries

Report frequency differs between centers in regard to entering data in Medscinet and YAWSA. Helsinki, Oslo, Tartu and Gothenburg are reporting pancreas data to YASWA. There have been legal uncertainties as to how we could report islet-data to registries outside the Nordics - CITR. There are also technical difficulties in transferring data from Medscinet to CITR. Perhaps we should close this question with CITR and refer to YASWA? ESOT has recently constructed a detailed registry. There are several uncertainties here. At least Torbjörn, Hanne and Ilse will set up a meeting to discuss this further and report to the next meeting of the group, if not before.

11. Working groups

Auto program: 7 auto transplants last year in Oslo. All these transplants are performed in Oslo. Gastro surgeon Anne Waage is responsible for the program. Discussion about a possible manuscript in Läkartidningen to increase knowledge about the treatment alternative.

Recruitment and endpoints: Important to start a working group to improve the numbers on our waiting lists. One working group should be able to define inclusion criteria and endpoints. Trond Jenssen coordinates the group and Torbjörn Lundgren, Hanne Scholz and Bengt von Zur-Mühlen joins.

12. Next meeting

Arlanda, physical meeting, 11th October 2023, start 10 AM, finished 3 PM.

13. The meeting ended

Uppsala 29th March 2023

Bengt von Zur-Mühlen
Secretary

Torbjörn Lundgren
Chairman